Stellular Bio
Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases
UndisclosedSeries A
Role not disclosedCI
Cockrell Interests
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Cockrell Interests is the investment entity named in financing coverage for Stellular Bio and ai3Bio.
Recorded funding activity
Stellular develops platelet-derived biologic therapies for ocular-surface diseases. ai3Bio develops antibody and lipid-nanoparticle approaches intended to remove disease-causing Th17 immune cells. The company records connect the same named investor to distinct therapeutic programs.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share